Advertisement

humira-abstracts

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.

PloS one 2016 09 0811(9) e0162316 doi 10.1371/journal.pone.0162316 Abstract OBJECTIVES With the present study we wanted to explore the impact of treatment with a tumor necrosis factor-α

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Management of psoriasis patients with hepatitis B or hepatitis C virus infection.

World journal of gastroenterology 22(28) 6444-55 doi 10.3748/wjg.v22.i28.6444 Abstract The systemic therapies available for the management of Psoriasis (PsO) patients who cannot be treated with more conservative

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange.

Scientific reports 2016 09 086() 32747 doi 10.1038/srep32747 Abstract Tumor necrosis factor (TNF) is a homotrimeric cytokine that is a key mediator of inflammation. It is unstable

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report.

Italian journal of pediatrics 2016 09 0642(1) 81 doi 10.1186/s13052-016-0291-2 Abstract BACKGROUND Autoimmune sensorineural hearing loss, also known as autoimmune inner ear disease (AIED) is a rare

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn’s disease – should one consider disease location? Authors’ reply.

Alimentary pharmacology & therapeutics 44(7) 772-3 doi 10.1111/apt.13768 Abstract

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn’s disease – should one consider disease location?

Alimentary pharmacology & therapeutics 44(7) 771-2 doi 10.1111/apt.13743 Abstract

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.

Journal of managed care & specialty pharmacy 22(9) 1088-102 doi 10.18553/jmcp.2016.22.9.1088 Abstract BACKGROUND Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis.

Scientific reports 2016 08 316() 32202 doi 10.1038/srep32202 Abstract While previous studies have researched in association analyses between TNFα promoter polymorphisms and responses to TNF blockers in

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.

Journal of managed care & specialty pharmacy 22(9) 1092-106 doi 10.18553/jmcp.2016.22.9.1092 Abstract BACKGROUND Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).

US-NLM-PubMed-Logo.svg
US-NLM-PubMed-Logo.svg

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels.

Rheumatology (Oxford, England) 2016 8 25() pii kew299 Abstract OBJECTIVE To determine the concordance between RIA and bridging ELISA at detecting anti-drug antibodies (ADAbs) in the context

[ HIDE/SHOW ]